University of Wisconsin Prostate SPORE

威斯康星大学前列腺孢子

• 批准号: 10555398
• 负责人: DAVID F. JARRARD
• 金额: $ 206.11万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10555398
• 关键词: 3-Dimensional; Ablation; Address; Adjuvant Study; Advanced Malignant Neoplasm; Androgen Receptor; Androgens; Area; Basic Science; Bioinformatics; Biological; Biomedical Engineering; Biometry; Cancer Patient; Castration; Cessation of life; Clinical; Clinical Trials; Combined Vaccines; Data; Development; Disease; Disease Progression; Environment; Feasibility Studies; Generations; Goals; Human; Image; Immune response; Immunology; Immunotherapy; Individual; Institution; Knowledge; Lesion; Link; Local Therapy; Malignant Neoplasms; Malignant neoplasm of prostate; Maps; Medical Oncologist; Metastatic Prostate Cancer; Modeling; Molds; Morbidity - disease rate; Neoadjuvant Therapy; Outcome; Pathology; Patient-Focused Outcomes; Patients; Phase I Clinical Trials; Positron-Emission Tomography; Preclinical Testing; Prostate; Prostatectomy; Quality of life; Radiation Oncologist; Radiology Specialty; Research; Research Personnel; Research Project Grants; Research Proposals; Research Support; Resistance; Resources; Scientist; Signal Transduction; Source; Specimen; Surgical Oncologist; Therapeutic; Time; Tissues; Translating; Translational Research; Treatment outcome; Universities; Wisconsin; abiraterone; advanced prostate cancer; androgen deprivation therapy; anticancer research; biochip; cancer therapy; career; castration resistant prostate cancer; clinical care; deprivation; diagnostic strategy; docetaxel; high risk; immune checkpoint blockade; immunomodulatory therapies; improved; improved outcome; inhibitor; men; molecular imaging; mortality; multidisciplinary; next generation; novel; novel diagnostics; novel strategies; patient response; pharmacologic; phase I trial; potential biomarker; programs; prostate cancer risk; receptor vaccine; response; success; therapeutic target; therapy resistant; translational goal; treatment response; treatment strategy; tumor; tumor heterogeneity; tumor microenvironment; vaccine evaluation

PROJECT SUMMARY The University of Wisconsin (UW) Prostate Cancer SPORE is a highly collaborative research proposal that links basic scientists with prostate cancer clinicians to advance treatment strategies for prostate cancer patients. The broad objectives of this SPORE are to: 1) Increase multidisciplinary translational research and develop the next generation of prostate cancer researchers, 2) Develop common resources to promote advances, 3) Translate promising new approaches into patients, and 4) Improve overall survival and quality of life for patients with prostate cancer. A crosscutting theme that encompasses this SPORE is understanding tumor resistance in advanced prostate cancer and exploiting this knowledge to improve patient outcomes. The UW Prostate Cancer SPORE has three primary research projects: 1) Tumor Microenvironment Initiators of the Metastatic Cascade in High-Risk Prostate Cancer, 2) Androgen Deprivation as an Immune Modulating Therapy in Combination with Targeted Immunotherapy of Prostate Cancer, and 3) Extending Clinical Benefit by Selective Treatment of Resistant Lesions in mCRPC. The SPORE will support this research with three Cores (Administrative, Integrated Pathology Radiology, and Biostatistics and Bioinformatics). The Career Enhancement Program and Developmental Research Program will engage new and established investigators and further translational goals in a rich multidisciplinary environment. When completed, the research of the UW Prostate Cancer SPORE will advance our treatments and understanding of prostate cancer and undoubtedly beneficially impact patients with this disease.

项目摘要 威斯康星州（UW）前列腺癌孢子的大学是一个高度合作的研究建议，链接 基础科学家与前列腺癌临床医生共同推进前列腺癌患者的治疗策略。的 该SPORE的主要目标是：1）增加多学科转化研究，并开发下一个 前列腺癌研究人员的一代，2）开发共同的资源，以促进进步，3）翻译 有前途的新方法进入患者，和4）提高总生存率和生活质量的患者， 前列腺癌围绕这一SPORE的一个横向主题是了解肿瘤耐药性， 晚期前列腺癌，并利用这些知识来改善患者的预后。前列腺癌的治疗方法 SPORE有三个主要研究项目：1）转移级联的肿瘤微环境启动子， 高风险前列腺癌，2）雄激素去甲肾上腺素作为免疫调节疗法与 前列腺癌的靶向免疫治疗，和3）通过选择性治疗扩大临床益处 mCRPC中的耐药病变。SPORE将通过三个核心（管理、集成、 病理学、放射学、生物统计学和生物信息学）。职业发展计划和 发展研究计划将吸引新的和已建立的研究人员和进一步的翻译目标 丰富的多学科环境。完成后，UW前列腺癌孢子的研究将 推进我们对前列腺癌的治疗和理解，无疑对前列腺癌患者产生了有益的影响。 这种疾病。